NIH Grants & Funding /
Clinical Trial: Not allowed
| FOA Number | Co-Funders | Title | Clinical Trial | Activity Code | Application Due Date |
|---|---|---|---|---|---|
| PAR-22-084 | National Cancer Institute (NCI) | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | Not allowed | R21 | ClosedJune 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025 |
| RFA-AI-21-078 | National Institute of Allergy and Infectious Diseases (NIAID) | RePORT International Coordinating Center (RICC) | Not allowed | U01 | ClosedMarch 17, 2022 |
| PAR-22-083 | National Cancer Institute (NCI) | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) | Not allowed | R01 | ClosedJune 05, 2023 | October 05, 2023 | February 05, 2024 | June 05, 2024 | October 05, 2024 | February 05, 2025 |
| PAR-22-054 | Office of Strategic Coordination (Common Fund) | Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program | Not allowed | X01 | ClosedFebruary 23, 2022 |
| RFA-DA-22-045 | National Center for Complementary and Integrative Health (NCCIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA) | HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic | Not allowed | R21 | ClosedMarch 10, 2022 |
| RFA-CA-22-056 | National Cancer Institute (NCI) | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) | Not allowed | R01 | ClosedDecember 16, 2023 |
| RFA-CA-22-057 | National Cancer Institute (NCI) | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) | Not allowed | R21 | ClosedDecember 16, 2023 |
| PAR-22-162 | National Cancer Institute (NCI) | Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) | Not allowed | U01 | Closed July 28, 2023 | February 28, 2024 | July 29, 2024 | February 28, 2025 |
| PAR-22-106 | National Cancer Institute (NCI) | Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | Not allowed | R03 | ClosedJune 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025 |
| RFA-NS-22-034 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS), National Center for Complementary and Integrative Health (NCCIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) | HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment | Not allowed | R01 | ClosedMarch 02, 2022 to October 02, 2024 |
| PAR-22-055 | National Institute of Neurological Disorders and Stroke (NINDS) | Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets | Not allowed | R61/R33 | ClosedMarch 15, 2022; March 14, 2023; and March 14, 2024 |
| PAR-21-122 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |
| PAR-21-123 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |
| PAR-21-124 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |